Will we cure cancer by sequencing thousands of genomes?

Molecular Cytogenetics
Joshua M Nicholson

Abstract

The promise to understand cancer and develop efficacious therapies by sequencing thousands of cancers has not occurred. Mutations in specific genes termed oncogenes and tumor suppressor genes are extremely heterogeneous amongst the same type of cancer as well as between cancers. They provide little selective advantage to the cancer and in functional tests have yet to be shown to be sufficient for transformation. Here I discuss the karyotyptic theory of cancer and ask if it is time for a new approach to understanding and ultimately treating cancer.

References

Mar 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·H Rubin, K Xu
Jun 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·R G GreigG Poste
Feb 1, 1983·American Journal of Medical Genetics·B L Shapiro
May 24, 1994·Proceedings of the National Academy of Sciences of the United States of America·N C DenkoP J Stambrook
Apr 10, 1997·Nature·C LengauerB Vogelstein
Sep 2, 1997·Proceedings of the National Academy of Sciences of the United States of America·V Y HuaP H Duesberg
Nov 16, 2002·Circulation Research·Lior Gepstein
Mar 3, 2004·Nature Reviews. Cancer·P Andrew FutrealMichael R Stratton
May 7, 2005·Nature Biotechnology·George L Gabor Miklos
May 2, 2006·Current Opinion in Genetics & Development·Heather HallTerry Hassold
Sep 9, 2006·Science·Tobias SjöblomVictor E Velculescu
May 16, 2007·Scientific American·Peter Duesberg
Oct 13, 2007·Science·Laura D WoodBert Vogelstein
Nov 6, 2007·Nature·Barbara A WeirMatthew Meyerson
Sep 6, 2008·Science·D Williams ParsonsKenneth W Kinzler
Nov 7, 2008·Nature·Timothy J LeyRichard K Wilson
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Sep 12, 2009·Annual Review of Pathology·Jesse J SalkLawrence A Loeb
Sep 29, 2009·Cancer Genetics and Cytogenetics·Joshua M Nicholson, Peter Duesberg
Feb 19, 2010·Nature·Rameen BeroukhimMatthew Meyerson
Jul 14, 2010·Cancer Genetics and Cytogenetics·Andreas KleinPeter Duesberg
Sep 30, 2010·Proceedings of the National Academy of Sciences of the United States of America·Ivana BozicMartin A Nowak
Mar 23, 2011·Cellular Oncology (Dordrecht)·Susanne Schulze, Iver Petersen
Mar 26, 2011·Science·Michael R Stratton
Jun 15, 2011·Cell Cycle·Peter DuesbergJoshua M Nicholson
Mar 9, 2012·The New England Journal of Medicine·Marco GerlingerCharles Swanton
Nov 6, 2012·International Journal of Cancer. Journal International Du Cancer·Pascal H G DuijfRobert Benezra
Jun 14, 2013·Frontiers in Oncology·Joshua M Nicholson, Daniela Cimini
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Jun 24, 2015·Academic Radiology·Saurabh Jha

❮ Previous
Next ❯

Citations

Jul 28, 2016·Biochemistry. Biokhimii︠a︡·E D Sverdlov

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Shu-xiao BaiJuan Shen
Nature Reviews. Cancer
Gemma K Alderton
© 2021 Meta ULC. All rights reserved